Percutaneous transcatheter aortic valve replacement induces femoral artery shrinkage: angiographic evidence and predictors for a new side effect. Issue 5 (25th October 2017)

• Record Type: Journal Article
• Authors: Shoeib, Osama; Burzotta, Francesco; Aurigemma, Cristina; Paraggio, Lazzaro; Viccaro, Fausta; Porto, Italo; Leone, Antonio Maria; Bruno, Piergiorgio; Trani, Carlo
• Is Part Of: Catheterization and cardiovascular interventions. Volume 91:Issue 5(2018)
• Page Start: 938
• Page End: 944
• Publication Date: 2017-10-25
• Subjects: angiography -- femoral artery -- peripheral artery disease -- TAVR; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.27248
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: We sought to investigate the possible impact of transaortic valve replacement (TAVR) on common femoral artery (CFA) integrity as assessed by angiography. Background: CFA represents the most adopted access for TAVR but various degrees of vascular damage may be induced by the procedure. Methods: Patients underwent percutaneous transfemoral TAVR who had both pre‐ and post‐TAVR access‐site angiography were retrospectively selected. Clinical and procedural data (including technique and complications) were prospectively recorded into a structured TAVR database. Pre‐TAVR and post‐TAVR angiograms were analyzed using a quantitative angiographic analysis software to assess reference diameters, minimum luminal diameter (MLD), and percentage of diameter stenosis (DS). Results: A total of 124 patients entered the study (mean age: 85 years, mean Euroscore II: 10%). ProStar (13.5%) and double ProGlide (82.2%) preclosure were the main hemostatic techniques. CFA exhibited a significant shrinkage with TAVR as assessed by significant MLD reduction (5.6 mm after TAVR vs. 6.8 mm before, P < .001) and DS increase (30.3% after vs. 17.0%, P < .001). Such differences remained statistically significant after exclusion of 18 patients (14.2%) who had (minor or major) vascular complications. At multivariable analysis, pre‐TAVR DS ( P = .03) and history of peripheral arterial disease ( P = .01), were significantly associated with vascular complications. Conclusions: Percutaneous TAVR induces an angiographically detectable CFA lumen reduction. Such findings call for further studies assessing clinical impact of this phenomenon and open the door for further refinements of the TAVR access management aimed at preserving vessel integrity.